Samsung's Two-Front Strategy: Biosimilar Profits Fuel a Future in Novel Drugs

INCHEON, Korea – July 24, 2026 – On the surface, the latest financial report from Samsung Epis Holdings paints a picture of steady, predictable success. The investment company’s core subsidiary, Samsung Bioepis, posted a solid 6% year-over-year growth in both revenue and operating profit for the first half of 2026, a testament to the resilience of its biosimilar portfolio. Yet, to see these figures as the whole story is to miss the plot entirely. Beneath the stable topline numbers, the company is executing a far more ambitious strategy: using its established biosimilar cash cow to fund a bold and calculated pivot into the high-stakes world of novel drug development.

This isn't just about growth; it's about transformation. Samsung is methodically architecting a future where it is not just a master of replication, but a pioneer of innovation, a move signaled by promising new cancer therapies and a strategic expansion of its global R&D footprint.

A Steady Hand in a Shifting Market

The foundation for this strategic pivot is the robust performance of Samsung Bioepis. The biopharmaceutical subsidiary recorded first-half revenues of 847.1 billion KRW and an operating profit of 230.6 billion KRW. This performance, anchored by a strong portfolio of biosimilars—near-identical, lower-cost versions of established biologic drugs—demonstrates a firm grasp on a complex and competitive global market.

“We delivered solid first-half 2026 results, achieving 6% growth year-over-year,” said Kyung-Ah Kim, President and CEO of Samsung Epis Holdings, in a statement. “This performance demonstrates the resilience of our biosimilar portfolio in the global market.”

While a slight dip in the second quarter, with revenue down 2% and operating profit down 4% compared to the prior year, might raise eyebrows, the company attributes this to shifting supply schedules and increased R&D investments rather than a softening of demand. The firm remains confident, with Kim noting that “increasing product demand in Europe and the US is expected to be reflected sequentially in the second-half results.”

This confidence is backed by aggressive commercial strategy. The company is moving away from reliance on partners and toward direct commercialization, a move that provides greater control over pricing and market access, ultimately securing better margins. This is evident in the recent European launch of OPUVIZ™, a biosimilar to the blockbuster eye medication Eylea, and the expanded U.S. presence of OSPOMYV®, a biosimilar for osteoporosis. Further cementing its global reach, the company entered the Japanese market in May through a partnership with NIPRO Corporation. This steady operational execution is what generates the capital and the stability required for a riskier, long-term game.

Beyond Replication: Betting on Next-Generation Therapeutics

The most telling indicators of Samsung's future direction lie deep within its R&D pipeline. The company made waves in June by announcing it was the first to report positive global Phase 3 results for a biosimilar candidate of Keytruda (pembrolizumab). Given that Keytruda is one of the world's best-selling cancer drugs, a successful biosimilar version represents a multi-billion-dollar opportunity. Securing a first-mover advantage in this race is a significant strategic victory.

But the ambition extends far beyond creating more affordable versions of existing medicines. The company is venturing into the frontier of novel therapeutics with SBE303, its first proprietary antibody-drug conjugate (ADC), which entered global Phase 1 clinical trials in March. ADCs are a sophisticated class of cancer therapy often described as “biological smart bombs,” engineered to deliver a potent toxin directly to cancer cells while sparing healthy tissue. SBE303 targets Nectin-4, a protein expressed in several aggressive cancers, including urothelial, lung, and breast cancer. Early data presented at the American Association for Cancer Research (AACR) Annual Meeting highlighted its anti-tumor efficacy and a promising safety profile, positioning it as a potentially significant new weapon in the oncology arsenal.

This is not a singular bet. The company confirmed a second ADC is in preclinical stages and is also exploring other high-value areas, including long-acting obesity treatments. This diversification signals a clear intent to evolve from a biosimilar specialist into a fully-fledged biopharmaceutical innovator, leveraging its deep expertise in biologics to create entirely new medicines.

Building a Global Footprint from Seoul to Shanghai

Orchestrating this two-front strategy is the parent company, Samsung Epis Holdings. The holding structure, established to separate strategic investment from day-to-day operations, allows it to channel the profits from the mature biosimilar business into the capital-intensive, long-horizon work of novel drug development. This structure is key to managing the different risk profiles and timelines of its two core missions.

A critical piece of this global architecture was put in place just last month with the establishment of the company's first overseas R&D center in China. This move is about more than just accessing a new market; it is a strategic play for talent, innovation, and speed. By embedding itself in one of the world's fastest-growing biotechnology ecosystems, Samsung gains access to a deep pool of scientific talent and can accelerate clinical development for the vast Asian market.

This deliberate global expansion—combining direct commercial muscle in the West with a new R&D hub in the East—forms a pincer movement designed to establish a dominant international presence. The company is no longer just a Korean success story; it is building the infrastructure of a global biopharma leader. While the headline financial figures suggest a business in a steady state, the strategic maneuvers underneath reveal a company in dynamic motion. The challenge ahead is immense: to defend its biosimilar market share against intensifying competition while simultaneously navigating the uncertain and costly path of bringing novel drugs from the lab to the patient. The pieces, however, are now clearly in place for this ambitious transformation.